{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:47:26Z","timestamp":1785757646985,"version":"3.56.0"},"reference-count":80,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Dev. Dis.","JCDD"],"abstract":"<jats:p>Conventional biomarkers provide useful information but often lack specificity due to age-related physiological variations or in the context of congenital heart disease (CHD). Proteomics uses new technologies to analyze hundreds to thousands of proteins simultaneously (multi-biomarker panels) and, combined with traditional ones (i.e., NT-BNP), it improves risk prediction and helps clinical decision making. In adults, there are clear efforts to improve risk prediction accuracy and personalized HF management strategies; meanwhile, more evidence must be established in the pediatric CHD population. This non-systematic review aims to give an overview of the limitations of conventional biomarkers and recently published literature on promising evolving biomarkers of the proteomic family that are applicable to the CHD population. Due to the highly complex physiology and interpretation of the anatomical variation of the biomarkers, it seems to be necessary for single markers to be tested in the pediatric population with various CHD anatomies and physiologies. Disease-specific validation is required, rather than assuming they behave the same way as they do in structurally normal hearts and adults.<\/jats:p>","DOI":"10.3390\/jcdd13080360","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:24:07Z","timestamp":1785752647000},"page":"360","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolving Proteomic Biomarkers in Children with Congenital Heart Defects"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7793-7051","authenticated-orcid":false,"given":"Martin","family":"Schweiger","sequence":"first","affiliation":[{"name":"Division of Cardiac and Vascular Surgery, University Children\u2019s Hospital Zurich, 8008 Zurich, Switzerland"},{"name":"Cardiac Surgery, Heart Center, King Faisal Specialist Hospital & Research Center, Riyadh 13338, Saudi Arabia"},{"name":"Children\u2019s Research Centre, University of Zurich, 8008 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4003-7655","authenticated-orcid":false,"given":"Clemens","family":"Haselmann","sequence":"additional","affiliation":[{"name":"Division of Cardiac and Vascular Surgery, University Children\u2019s Hospital Zurich, 8008 Zurich, Switzerland"},{"name":"Children\u2019s Research Centre, University of Zurich, 8008 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3575-6647","authenticated-orcid":false,"given":"Robert","family":"Cesnjevar","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, University Hospital Erlangen, Friedrich Alexander University Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1161\/CIR.0000000000000490","article-title":"Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association","volume":"135","author":"Chow","year":"2017","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s00246-025-03935-0","article-title":"Exploring Serum Biomarker Levels in Tetralogy of Fallot, Hypoplastic Left Heart Syndrome, and Healthy Children","volume":"47","author":"Vargas","year":"2026","journal-title":"Pediatr. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/0006-291X(90)92401-K","article-title":"C-Type natriuretic peptide (CNP): A new member of natriuretic peptide family identified in porcine brain","volume":"168","author":"Sudoh","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/332078a0","article-title":"A new natriuretic peptide in porcine brain","volume":"332","author":"Sudoh","year":"1988","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Asta, L., Pisano, C., Sbrigata, A., Raffa, G.M., Scola, L., and Balistreri, C.R. (2025). Biomarkers in Heart Failure: A Review and a Wish. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26168046"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00246-008-9258-4","article-title":"NT-pro-B-type natriuretic peptide in infants and children: Reference values based on combined data from four studies","volume":"30","author":"Nir","year":"2009","journal-title":"Pediatr. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.cardfail.2005.04.009","article-title":"Clinical value of NT-ProBNP and BNP in pediatric cardiology","volume":"11","author":"Nir","year":"2005","journal-title":"J. Card. Fail."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3892\/etm.2013.1250","article-title":"Role of the NT-proBNP level in the diagnosis of pediatric heart failure and investigation of novel combined diagnostic criteria","volume":"6","author":"Lin","year":"2013","journal-title":"Exp. Ther. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1515\/cclm-2023-0977","article-title":"Reference intervals for high sensitivity cardiac troponin I and N-terminal pro-B-type natriuretic peptide in children and adolescents on the Siemens Atellica","volume":"62","author":"Ameh","year":"2024","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jalm\/jfad012","article-title":"Comprehensive Pediatric Reference Limits for High-Sensitivity Cardiac Troponin I and NT-proBNP in the CALIPER Cohort","volume":"8","author":"Bohn","year":"2023","journal-title":"J. Appl. Lab. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Wang, Q., Liu, G., Teng, Y., Feng, X., Chen, Z., Wang, F., Gu, Y., Jia, L., Cao, J.J., and Lu, Z.X. (2023). Diagnostic value of peripheral TiM-3, NT proBNP, and Sestrin2 testing in left-to-right shunt congenital heart disease with heart failure. BMC Pediatr., 23.","DOI":"10.1186\/s12887-022-03823-z"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1023\/A:1026195332025","article-title":"B-type natriuretic peptide and renal disease","volume":"8","author":"McCullough","year":"2003","journal-title":"Heart Fail. Rev."},{"key":"ref_15","first-page":"728","article-title":"Diagnostic value of the currently used criteria and brain natriuretic peptide for diagnosing congestive heart failure in children with congenital heart disease","volume":"44","author":"Wu","year":"2006","journal-title":"Zhonghua Er Ke Za Zhi Chin. J. Pediatr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s00246-024-03489-7","article-title":"NT-proBNP for Predicting All-Cause Death and Heart Transplant in Children and Adults with Heart Failure","volume":"46","author":"Schmitt","year":"2025","journal-title":"Pediatr. Cardiol."},{"key":"ref_17","first-page":"100670","article-title":"NT-proBNP and other blood biomarkers in patients after Fontan Surgery: Prognostic, diagnostic, and management implications","volume":"24","author":"Ahmed","year":"2026","journal-title":"Int. J. Cardiol. Congenit. Heart Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3300884","DOI":"10.1155\/2021\/3300884","article-title":"Value of Follow-Up N-Terminal Probrain Natriuretic Peptide (NT-proBNP) after a Modified Fontan Procedure","volume":"2021","author":"Li","year":"2021","journal-title":"Cardiol. Res. Pract."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jacc.2012.12.044","article-title":"B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction","volume":"61","author":"Linssen","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.amjcard.2008.04.048","article-title":"Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction","volume":"102","author":"Grewal","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1007\/s00246-025-03898-2","article-title":"Impact of Systemic Ventricular Morphology on Age-Adjusted (zlog-)NT-proBNP in Children with Univentricular Hearts","volume":"47","author":"Palm","year":"2026","journal-title":"Pediatr. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.tips.2023.06.001","article-title":"Targeting galectin-3 in inflammatory and fibrotic diseases","volume":"44","author":"Bouffette","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1113\/EP091277","article-title":"Circulating Gal-3 and sST2 are associated with acute exercise-induced sustained endothelial activation: Possible relevance for fibrosis development?","volume":"108","author":"Beltrami","year":"2023","journal-title":"Exp. Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2012.04.053","article-title":"Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community","volume":"60","author":"Ho","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10741-021-10105-w","article-title":"Biomarkers for the diagnosis and management of heart failure","volume":"27","author":"Castiglione","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"ref_26","first-page":"323","article-title":"Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: Data from the DEAL-HF study","volume":"99","author":"Lok","year":"2010","journal-title":"Clin. Res. Cardiol. Off. J. Ger. Card. Soc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e002706","DOI":"10.1161\/JAHA.115.002706","article-title":"Galectin-3 Is Elevated and Associated With Adverse Outcomes in Patients With Single-Ventricle Fontan Circulation","volume":"5","author":"Opotowsky","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5603\/cj.99070","article-title":"Galectin-3: Heart failure biomarker in pediatric heart defects","volume":"32","author":"Gondko","year":"2025","journal-title":"Cardiol. J."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Smereczy\u0144ska-Wierzbicka, E., Pietrzak, R., and Werner, B. (2022). A Scoping Review of Galectin-3 as a Biomarker of Cardiovascular Diseases in Pediatric Populations. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19074349"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Saleh, N., Khattab, A., Rizk, M., Salem, S., and Abo-Haded, H. (2020). Value of Galectin-3 assay in children with heart failure secondary to congenital heart diseases: A prospective study. BMC Pediatr., 20.","DOI":"10.1186\/s12887-020-02427-9"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e014569","DOI":"10.1161\/JAHA.119.014569","article-title":"Biomarkers of Inflammation and Fibrosis in Kawasaki Disease Patients Years After Initial Presentation With Low Ejection Fraction","volume":"9","author":"Hoshino","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13054-021-03538-0","article-title":"Galectin-3 in septic acute kidney injury: A translational study","volume":"25","author":"Sun","year":"2021","journal-title":"Crit. Care"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3000605251406969","DOI":"10.1177\/03000605251406969","article-title":"The prognostic value of circulating soluble ST2 in patients with chronic heart failure","volume":"54","author":"Zhang","year":"2026","journal-title":"J. Int. Med. Res."},{"key":"ref_34","unstructured":"Shengelia, T., Tsinamdzgvrishvili, B., Nadaraia, K., Liluashvili, K., and Talakvadze, T. (2024). Prognostic significance of sst2 in heart failure with reduced ejection fraction, a biomarker of cardiovascular mortality and rehospitalization. Georgian Med. News, 6\u201312."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.jacc.2018.08.2165","article-title":"sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T","volume":"72","author":"Emdin","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_36","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","article-title":"2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"23","author":"Yancy","year":"2017","journal-title":"J. Card. Fail."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Laqqan, M., Schwaighofer, C., Graeber, S., and Raedle-Hurst, T. (2018). Predictive value of soluble ST2 in adolescent and adult patients with complex congenital heart disease. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0202406"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Sulu, A., Uner, G., Kosger, P., and Ucar, B. (2024). Does the ST2 Level in Pediatric Heart Failure Patients Correlate with Cardiovascular Events and Mortality?. Children, 11.","DOI":"10.3390\/children11060718"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.chest.2019.12.037","article-title":"Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension","volume":"157","author":"Simpson","year":"2020","journal-title":"Chest"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.clinbiochem.2015.08.007","article-title":"Soluble ST2 and galectin-3 in pediatric patients without heart failure","volume":"48","author":"Meeusen","year":"2015","journal-title":"Clin. Biochem."},{"key":"ref_42","first-page":"727","article-title":"Association of Soluble ST2 Serum Levels With Outcomes in Pediatric Dilated Cardiomyopathy","volume":"35","author":"You","year":"2019","journal-title":"Can. J. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1136\/heartjnl-2016-309460","article-title":"Diagnostic performance and reference values of novel biomarkers of paediatric heart failure","volume":"102","author":"Hauser","year":"2016","journal-title":"Heart"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/heartjnl-2018-314168","article-title":"Prognostic value of soluble ST2 in adults with congenital heart disease","volume":"105","author":"Geenen","year":"2019","journal-title":"Heart"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e015022","DOI":"10.1161\/JAHA.119.015022","article-title":"Associations Between Blood Biomarkers, Cardiac Function, and Adverse Outcome in a Young Fontan Cohort","volume":"10","author":"Bossers","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"11514","DOI":"10.1073\/pnas.94.21.11514","article-title":"MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily","volume":"94","author":"Bootcov","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Lombardi, C., Marandola, M., Loria, V., Urbani, A., and Baroni, S. (2026). Growth Differentiation Factor-15 as an Emerging Biomarker in Cardiology: Diagnostic and Prognostic Implications. J. Pers. Med., 16.","DOI":"10.3390\/jpm16010016"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"glae163","DOI":"10.1093\/gerona\/glae163","article-title":"Growth Differentiation Factor 15 as a Biomarker of Cardiovascular Risk in Chronic Musculoskeletal Pain","volume":"79","year":"2024","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11897-023-00610-4","article-title":"Growth Differentiation Factor 15 (GDF-15), a New Biomarker in Heart Failure Management","volume":"20","author":"Sawalha","year":"2023","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1373\/clinchem.2016.255174","article-title":"Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease","volume":"63","author":"Wollert","year":"2017","journal-title":"Clin. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/clc.23159","article-title":"Growth differentiation factor-15 and the risk of cardiovascular diseases and all-cause mortality: A meta-analysis of prospective studies","volume":"42","author":"Xie","year":"2019","journal-title":"Clin. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.106.650846","article-title":"Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome","volume":"115","author":"Wollert","year":"2007","journal-title":"Circulation"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/eurheartj\/ehn600","article-title":"Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction","volume":"30","author":"Khan","year":"2009","journal-title":"Eur. Heart J."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Barbosa, M., Martins, M.A., Fernandes-Silva, J., Mel\u00edcio, A., and Martins, \u00c1.M. (2026). The Role of GDF-15 in Heart Failure and Biomarker Potential-From Basic Science to Clinical Praxis. Biology, 15.","DOI":"10.20944\/preprints202602.1687.v1"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e35916","DOI":"10.1016\/j.heliyon.2024.e35916","article-title":"Association between growth differentiation factor-15 and adverse outcomes among patients with heart failure: A systematic literature review","volume":"10","author":"Javaheri","year":"2024","journal-title":"Heliyon"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ahj.2011.03.036","article-title":"Growth differentiation factor 15: An additional diagnostic tool for the risk stratification of developing heart failure in patients with operated congenital heart defects?","volume":"162","author":"Norozi","year":"2011","journal-title":"Am. Heart J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1177\/21501351221118080","article-title":"Growth Differentiation Factor 15: A Novel Growth Biomarker for Children With Congenital Heart Disease","volume":"13","author":"Paneitz","year":"2022","journal-title":"World J. Pediatr. Congenit. Heart Surg."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/eurheartj\/ehac681","article-title":"Growth differentiation factor 15: A biomarker searching for an indication","volume":"44","author":"Mueller","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.0953-8194.2004.01172.x","article-title":"Regulatory mechanisms of corticotropin-releasing hormone and vasopressin gene expression in the hypothalamus","volume":"16","author":"Itoi","year":"2004","journal-title":"J. Neuroendocrinol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2005.02.095","article-title":"Vasopressin antagonism in heart failure","volume":"46","author":"Goldsmith","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","article-title":"Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin","volume":"52","author":"Morgenthaler","year":"2006","journal-title":"Clin. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1161\/CIRCULATIONAHA.106.685503","article-title":"C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study","volume":"115","author":"Khan","year":"2007","journal-title":"Circulation"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jacc.2009.01.076","article-title":"Incremental value of copeptin for rapid rule out of acute myocardial infarction","volume":"54","author":"Reichlin","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00380-022-02123-x","article-title":"Copeptin plus troponin in the rapid rule out of acute myocardial infarction and prognostic value on post-myocardial infarction outcomes: A systematic review and diagnostic accuracy study","volume":"38","author":"Elseidy","year":"2023","journal-title":"Heart Vessel"},{"key":"ref_65","first-page":"570","article-title":"Use of copeptin for rapid rule-out of acute myocardial infarction","volume":"7","author":"Mueller","year":"2018","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Mu, D., Cheng, J., Qiu, L., and Cheng, X. (2022). Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.901990"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cca.2017.10.001","article-title":"Copeptin in heart failure: Review and meta-analysis","volume":"475","author":"Zhong","year":"2017","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Netala, V.R., Hou, T., Wang, Y., Zhang, Z., and Teertam, S.K. (2025). Cardiovascular Biomarkers: Tools for Precision Diagnosis and Prognosis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26073218"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1007\/s00431-021-04060-9","article-title":"Plasma copeptin levels in children with pulmonary arterial hypertension associated with congenital heart disease","volume":"180","author":"Gaheen","year":"2021","journal-title":"Eur. J. Pediatr."},{"key":"ref_70","first-page":"e15355","article-title":"Serum copeptin as a biomarker of hypertension in children with obesity","volume":"64","author":"Gor","year":"2022","journal-title":"Pediatr. Int. Off. J. Jpn. Pediatr. Soc."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s13312-024-3330-x","article-title":"Plasma Copeptin as a Prognostic Marker in Children with Heart Failure","volume":"61","author":"Abdelaziz","year":"2024","journal-title":"Indian Pediatr."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Karki, K.B., Towbin, J.A., Shah, S.H., Philip, R.R., West, A.N., Tadphale, S.D., and Saini, A. (2023). Elevated Copeptin Levels Are Associated with Heart Failure Severity and Adverse Outcomes in Children with Cardiomyopathy. Children, 10.","DOI":"10.3390\/children10071138"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Meagher, P.B., Lee, X.A., Lee, J., Visram, A., Friedberg, M.K., and Connelly, K.A. (2021). Cardiac Fibrosis: Key Role of Integrins in Cardiac Homeostasis and Remodeling. Cells, 10.","DOI":"10.3390\/cells10040770"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ejhf.696","article-title":"Myocardial fibrosis: Biomedical research from bench to bedside","volume":"19","author":"Winkler","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s12519-015-0039-x","article-title":"Cardiac biomarkers in children with congenital heart disease","volume":"11","author":"Sugimoto","year":"2015","journal-title":"World J. Pediatr."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.jtcvs.2016.01.020","article-title":"Ventricular fibrogenesis activity assessed by serum levels of procollagen type III N-terminal amino peptide during the staged Fontan procedure","volume":"151","author":"Sugimoto","year":"2016","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"399","DOI":"10.36348\/sjm.2025.v10i08.004","article-title":"Study of New Biomarkers as Potential Predictors in Pediatric Dilated Cardiomyopathy","volume":"10","author":"Mahmoud","year":"2025","journal-title":"Saudi J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Risteli, J., and Risteli, L. (1989). Markers of Collagen Assembly and Turnover. Clinical Impact of Bone and Connective Tissue Markers, Elsevier.","DOI":"10.1016\/B978-0-12-450740-1.50019-6"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1203\/00006450-198802000-00008","article-title":"Long-term monitoring of treatment with recombinant human growth hormone by serial determinations of type III procollagen-related antigens in serum","volume":"23","author":"Danne","year":"1988","journal-title":"Pediatr. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jacc.2025.09.006","article-title":"2025 ACC\/AHA\/HRS\/ISACHD\/SCAI Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Gurvitz","year":"2026","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/13\/8\/360\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:14:24Z","timestamp":1785755664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/13\/8\/360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":80,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcdd13080360"],"URL":"https:\/\/doi.org\/10.3390\/jcdd13080360","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}